J&J-backed Cellular Origins raises $40M for cell therapy manufacturing
Cellular Origins, a TTP Group company, has closed a $40 million over-subscribed Series A round to scale its cell therapy manufacturing platform.
The financing was led by Johnson & Johnson Innovation – JJDC, Inc., with participation from Highland Europe, BGF, NYBC Ventures, and TTP Group.
The funds will accelerate development and deployment of the Constellation robotic automation platform, which integrates third-party bioprocess instruments to enable scalable, reliable, and space-efficient cell therapy production.
Cellular Origins is trusted by major industry players including Cytiva, Fresenius Kabi, Thermo Fisher Scientific, and Wilson Wolf.
The company will use the investment to expand its commercial team, broaden integrated unit operations, build manufacturing and service infrastructure, and extend capabilities into the broader Advanced Therapies Medicinal Products (ATMP) sector.
Cellular Origins is also collaborating with Johnson & Johnson to develop a scalable, end-to-end automated platform for autologous CAR-T cell therapies, and has strategic partnerships with Cytiva and Thermo Fisher Scientific to integrate their technologies into the Constellation platform.